A randomized, double-blind, placebo-controlled Phase III study of darolutamide (ODM-201) versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer

Trial Profile

A randomized, double-blind, placebo-controlled Phase III study of darolutamide (ODM-201) versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Jul 2018

At a glance

  • Drugs Antiandrogens (Primary) ; Darolutamide (Primary) ; Docetaxel (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Acronyms ARASENS
  • Sponsors Bayer
  • Most Recent Events

    • 16 Feb 2018 Trial design presented at the 2018 Genitourinary Cancers Symposium.
    • 08 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
    • 01 Sep 2017 According to a Bayer media release, data from this trial will be presented at the European Society for Medical Oncology (ESMO) Congress in Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top